Log In

 
Company : Medical Technology Association of India (MTaI) 
Thursday, January 5, 2017 5:10PM IST (11:40AM GMT)
 
MTaI Committed to Fair & Transparent Mechanism of Stent Pricing that Accounts for the Innovative Nature of MedTech Sector
New Delhi, Delhi, India

  • Expresses concern over a selective outflow of altered pricing data in media and discrimination against a few research-based companies
  • Submits stent differentiation matrix mechanism to the government for review
  • Underscores need for a process that drives accountability from all stakeholders, leading finally to the benefit of price reduction reaching patients
 
The Medical Technology Association of India (MTaI) has been proactively and collaboratively working with the authorities in the process on pricing discussions over the past many months. We are committed to have a fair and transparent mechanism of pricing which accounts for the innovative nature of the sector. 

While we have been co-operating with all the authorities in these discussions, and our member companies were among the first to submit the required data, we are deeply concerned by seeing a selective outflow of altered pricing data in a few media reports this week. The reports selectively targeted only a few research-based companies while leaving a larger pool of more than 20 other companies out of the story. We urge all the stakeholders to bring a broader perspective covering information about all other companies instead of discriminating against a few research-based companies.

The details of pricing as presented by MTaI members, as well as those that have been released in the press this week (if these are correct) point out to the vital importance of bringing all the constituents to the discussion table and place a process that drives accountability from all stakeholders, leading finally to the benefit of price reduction reaching patients.

A stent differentiation matrix mechanism, which would have helped differentiate different generations of drug eluting stents based on usage, safety data, publications and other measurable parameters, has been structured by MTaI in collaboration with leading cardiologists across India and submitted to the government for review. Done properly, a simplified version of this differentiation matrix can help define stent prices and also become a pioneering effort for other countries to implement.

MTaI believes that a nascent sector like medical devices which accounts for less than 2% of the overall healthcare sector of India; needs support with policies which encourage technology innovation, clinical evidence and strong quality management systems to ensure best patient outcomes. Initiatives like ‘Make in India’ would lose on a major opportunity to generate highly skilled employment in absence of clear and rational policy framework. A knee-jerk policy framework without accounting for innovation, will not only make India unviable to be a global destination for medical device manufacturing but will also reduce India’s competitiveness to provide world-class and highly advance medical care to patient from India and abroad.

We appreciate the inclusive nature of the NPPA meeting agenda and hope our suggestions will be taken on board. We are willing to have the views we have put forth corroborated and the data we have presented verified and expect that the remaining quarters of the industry will come forward with their data by the new deadline of 9th January, 2017 as has been kindly extended by the Chairman NPPA for them.
 
About MTaI

Medical Technology Association of India (MTaI – pronounced as Em-tai) is a not-for- profit organisation duly registered under sub-section (2) of section 7 of the Companies Act, 2013 and Rule 8 of the Companies (Incorporation) Rules, 2014.
 
MTaI is an association of research-based medical technology companies who have made remarkable investments by setting up large number of R&D centres and manufacturing plants in India. MTaI represents a wide spectrum of the medical device and equipment industry with global experience in innovation and manufacturing. All the time stressing on the three hallmarks of healthcare - Quality, Consistency and Patient Safety, MTaI want to be a responsible voice of the industry. The association is committed to improving access to affordable and quality healthcare for patients.
 
MTaI looks to partner with Government of India in setting a roadmap for growth of medical devices sector by bringing in even bigger investments in this sector, through 'Make in India and through technology upgradation and dissemination in the provider space. 

 
For News Release background on Medical Technology Association of India (MTaI) click here
 
Media Contact Details
Namrata Bhalla, Footprint Global Communications, +91-9873169803, namrata.bhalla@footprintglobal.com
Ruchika Sharma, Footprint Global Communications, +91-9560877908, ruchika.sharma@footprintglobal.com
Aashwin George Philip, Footprint Global Communications, +91-7503453192, aashwin.philip@footprintglobal.com
 
 
Submit your press release
More News from Medical Technology Association of India (MTaI)

23/04/2017 12:30PM

MTaI Welcomes PMO's Intervention on the Forthcoming National Medical Device Policy

MTaI welcomes PMO's intervention on the forthcoming National Medical Device Policy.

Similar News

18/08/2017 7:38PM

Sagoon Reopens its Reg A "Mini IPO" for the Second Round of Public Investment

Sagoon (www.sagoon.com), a social commerce start up with operations in the United States and India, announced in a small gathering in London today that it is reopening an investment opportunity to a massive pool of ...

No Image

18/08/2017 4:23PM

The Blockchain Revolution and its Impact on Asset Management

The Finance Club of MISB Bocconi organized 'Finance Conclave 2017' in Mumbai. The topic of discussion was 'The Blockchain Revolution and its impact on Asset Management'. Through the conclave, the club addressed the ...